Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 4, 2015, primarily to report its financial and operating results for the second quarter ended June 30, 2015. The press release containing these results, dated August 4, 2015, is furnished as an exhibit. Investors should note that this information is being furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, unless specifically incorporated into a future filing. Additionally, Regeneron announced its intention to utilize its corporate website and Twitter feed for disseminating important company information, including material to investors. This expanded communication strategy supplements traditional channels like SEC filings, press releases, and conference calls, prompting investors to actively monitor these platforms for updates.
Key Highlights
- 1Regeneron announced its second quarter 2015 financial and operating results via a press release dated August 4, 2015.
- 2The press release is furnished as Exhibit 99.1 to the 8-K filing.
- 3Financial and operating results for the quarter ended June 30, 2015, are disclosed.
- 4Information furnished in this Item 2.02 is not considered "filed" for Section 18 of the Exchange Act purposes unless expressly incorporated.
- 5Regeneron will use its website and Twitter feed to publish important company information, including material for investors.
- 6Investors are encouraged to monitor these social media channels in addition to traditional SEC filings and press releases.